Adenosquamous cell lung cancer stage IV is a rare and aggressive form of lung cancer that combines features of two different cancer types, creating unique challenges in diagnosis and treatment. This advanced stage means the cancer has spread beyond the lungs to other parts of the body, requiring specialized approaches to care.
What Is Adenosquamous Cell Lung Cancer?
Adenosquamous carcinoma of the lung, often shortened to ASC, is a relatively uncommon subtype of non-small cell lung cancer, which is the broader category of lung cancers that grow more slowly than small cell lung cancer. What makes ASC unique is that it contains components of two different types of cancer cells: adenocarcinoma cells and squamous cell carcinoma cells. According to the World Health Organization classification, to be diagnosed as ASC, each of these two cell types must make up at least 10 percent of the tumor.[1]
Adenocarcinoma typically begins in the cells that produce mucus and usually occurs in the outer regions of the lungs. Squamous cell carcinoma, on the other hand, forms in the flat cells that line the airways and is typically found in the central parts of the lungs near the major airways. When these two cell types exist together in one tumor, they create adenosquamous carcinoma.[2][3]
Although ASC has biological characteristics of both adenocarcinoma and squamous cell carcinoma, it is not simply a blend of the two. It has its own distinct behavior and characteristics. This type of lung cancer accounts for approximately 2 to 4 percent of all lung cancer cases, making it quite rare compared to other lung cancer subtypes.[4][5]
Understanding Stage IV
When adenosquamous cell lung cancer reaches stage IV, it means the disease has spread beyond its original location in the lungs. This is also called metastatic cancer, meaning it has traveled to distant parts of the body. Stage IV lung cancer can spread to the other lung, to the fluid surrounding the lungs, to the fluid around the heart, or to organs and tissues outside the chest area.[2]
Stage IV is divided into two substages. Stage IVA typically involves cancer that has spread within the chest cavity or to one distant site. Stage IVB means the cancer has spread more widely to multiple distant organs or locations. This advanced stage represents the most serious form of lung cancer and requires comprehensive treatment approaches.[2]
Epidemiology: Who Gets This Disease?
Like other types of lung cancer, adenosquamous carcinoma tends to affect people in their later years. The average age at diagnosis is around 70 years old. Studies have consistently shown that this cancer affects more men than women, though women can certainly develop it as well.[4]
The majority of patients diagnosed with ASC are either current smokers or have a history of smoking. This pattern mirrors what we see with other types of lung cancer, where tobacco use plays a major role. However, it’s important to note that non-smokers can also develop this disease, though this occurs less frequently.[4]
Because ASC is such a rare subtype, representing only 2 to 4 percent of all lung cancers, large-scale epidemiological data is limited. Most of what we know comes from smaller studies and case reports. This rarity also means that many healthcare providers may have limited experience with this particular cancer type, which can impact both diagnosis and treatment planning.[4]
Causes and Risk Factors
The primary cause of adenosquamous carcinoma of the lung, like most lung cancers, is tobacco smoking. Cigarette smoke contains thousands of chemicals, many of which are known to damage the DNA in lung cells. This damage can cause cells to grow abnormally and eventually develop into cancer. The more a person smokes and the longer they smoke, the higher their risk becomes.[3]
Beyond smoking, other risk factors may contribute to the development of this cancer. Exposure to secondhand smoke, even if you don’t smoke yourself, increases risk. Environmental and occupational exposures to substances like asbestos, radon gas, or certain industrial chemicals can also damage lung tissue over time and raise cancer risk.[3]
Genetic factors may also play a role. Some studies have found that adenosquamous carcinomas can have specific genetic mutations or changes. For example, about 30 percent of ASC cases show EGFR mutations, which are changes in the epidermal growth factor receptor gene. Around 25 percent show p53 mutations, and about 5 percent have ALK rearrangements. These genetic changes affect how cells grow and divide, contributing to cancer development.[4]
It’s worth noting that the exact origin of adenosquamous carcinoma remains somewhat unclear. Scientists believe it may develop from a single stem cell that then differentiates into two different cell types, or it could arise from two separate cancer types that eventually merge. Understanding these mechanisms is still an active area of research.[4]
Symptoms of Advanced Disease
When adenosquamous cell lung cancer reaches stage IV, symptoms can be wide-ranging and often severe because the cancer has spread beyond the lungs. Common respiratory symptoms include persistent coughing that doesn’t go away or gets worse over time. This cough may produce blood or rust-colored mucus, which can be alarming and should always prompt medical attention.[3]
Shortness of breath is another common symptom, occurring as the tumor interferes with normal lung function or if fluid builds up around the lungs. Patients may feel winded even with minimal activity or at rest. Chest pain can occur, sometimes described as a persistent ache or pressure that may worsen with deep breathing, coughing, or laughing.[3]
Because stage IV means the cancer has spread to other parts of the body, patients may experience symptoms related to where the cancer has metastasized. If cancer spreads to bones, it can cause persistent bone pain. Spread to the brain may cause headaches, changes in vision, balance problems, or seizures. Liver involvement might lead to jaundice (yellowing of the skin and eyes) or abdominal pain.[3]
General symptoms of advanced cancer often include unexplained weight loss, sometimes significant. Patients may lose their appetite and feel constantly tired or weak. Some people develop a hoarse voice if the cancer affects nerves that control the voice box. Recurrent lung infections like bronchitis or pneumonia may also occur more frequently.[3]
The Challenge of Diagnosis
Diagnosing adenosquamous carcinoma before surgery is extremely difficult, and this poses significant challenges for patients and doctors. The mixed nature of the tumor, containing two different cell types, means that small biopsy samples may only capture one component of the cancer. This can lead to an initial diagnosis of either pure adenocarcinoma or pure squamous cell carcinoma, missing the true adenosquamous nature.[1][5]
Studies have shown that ASC is misdiagnosed or not fully diagnosed before surgery in at least half of cases. In one retrospective study, nearly all ASC cases (98 percent) were either misdiagnosed or remained undiagnosed before surgery confirmed the actual diagnosis. Different types of biopsy samples can even yield different results in the same patient.[4]
The gold standard for adequate diagnosis remains pathology examination of surgically resected tissue, where the entire tumor can be evaluated. However, in stage IV disease, surgery to remove the tumor is often not possible because the cancer has spread too widely. This means diagnosis relies on biopsy samples, which may not tell the complete story.[1][5]
To improve diagnostic accuracy, doctors may need to take multiple core biopsies from different areas of the tumor. Complete evaluation of the entire tumor specimen, when possible, helps in subclassifying ASC according to the proportions of adenocarcinoma and squamous cell carcinoma components present. This classification can provide additional information about prognosis.[4]
Prevention Strategies
The most effective prevention strategy for adenosquamous cell lung cancer is to never start smoking, or to quit if you currently smoke. Smoking cessation reduces lung cancer risk significantly over time, though it takes years for risk to decrease substantially. Even for people already diagnosed with lung cancer, quitting smoking can improve treatment outcomes and overall health.[3]
Avoiding secondhand smoke is also important. If you live or work with smokers, encourage them to smoke outside and away from others. This protects not only you but also children and other vulnerable individuals who may be exposed. Creating smoke-free environments in homes and workplaces reduces everyone’s risk.[3]
For people at high risk of lung cancer, screening with low-dose CT scans can detect lung cancer at earlier stages when it’s more treatable. Screening is recommended for adults aged 50 to 80 who have a significant smoking history and currently smoke or have quit within the past 15 years. While screening won’t prevent cancer, finding it early can make a substantial difference in outcomes.[2]
Reducing exposure to known lung carcinogens is also protective. This includes testing homes for radon gas, which can accumulate in basements and is a known cause of lung cancer. People who work with asbestos, certain chemicals, or other hazardous materials should follow safety protocols including wearing protective equipment and ensuring proper ventilation.[3]
How the Disease Affects the Body
Understanding what happens in the body when adenosquamous cell lung cancer develops helps explain the symptoms and complications patients experience. Normal lung cells have regulated growth patterns, dividing and dying in an orderly way. When cells become cancerous, they acquire mutations that allow them to grow uncontrollably, ignore signals to stop dividing, and avoid normal cell death.[2]
As the tumor grows in the lung, it can block airways, making it harder for air to flow in and out. This causes shortness of breath and can trap air behind the blockage, leading to infections. The tumor can also invade blood vessels, which explains why some patients cough up blood. As cancer cells multiply, they form masses that compress surrounding normal lung tissue, reducing the lung’s ability to exchange oxygen and carbon dioxide effectively.[2]
In stage IV disease, cancer cells break away from the primary tumor and travel through the bloodstream or lymphatic system to distant sites. When these cells land in other organs, they can establish new tumors called metastases. Each location where cancer spreads can cause specific problems. Bone metastases can weaken bones and cause pain or fractures. Brain metastases can increase pressure inside the skull, causing neurological symptoms. Liver metastases can interfere with the liver’s ability to filter blood and produce essential proteins.[2]
The cancer also affects the body systemically. Tumor cells can release substances that suppress appetite and alter metabolism, leading to weight loss and muscle wasting called cachexia. The immune system becomes activated trying to fight the cancer, which contributes to fatigue and weakness. As cancer spreads and grows, it increasingly interferes with normal organ function, eventually affecting multiple body systems.[2]
Adenosquamous carcinoma specifically shows some unique pathophysiological features. Studies indicate it tends to have higher rates of lymph node involvement at diagnosis compared to pure adenocarcinoma or squamous cell carcinoma. This suggests the cancer cells have greater ability to invade lymphatic channels and spread early in the disease course. The dual nature of the cancer, with both adenocarcinoma and squamous components, may give it biological advantages that make it more aggressive.[4]
Treatment Approaches for Stage IV Disease
Treatment for stage IV adenosquamous cell lung cancer focuses on controlling the disease, relieving symptoms, and maintaining quality of life. Because the cancer has spread beyond the lungs, cure is generally not possible, but treatments can help people live longer and feel better. The specific treatment plan depends on several factors including the extent of spread, genetic characteristics of the tumor, and the patient’s overall health.[7]
Chemotherapy remains a cornerstone of treatment for stage IV disease. If genetic testing doesn’t reveal specific mutations that can be targeted with other drugs, chemotherapy may be the first treatment offered. The most common chemotherapy combination uses platinum-based drugs like cisplatin or carboplatin paired with another agent such as gemcitabine. For ASC specifically, combinations like taxol and carboplatin may be used to target both the adenocarcinoma and squamous components of the tumor.[7]
Other chemotherapy combinations that may be considered include cisplatin or carboplatin with docetaxel, carboplatin with paclitaxel, gemcitabine with docetaxel, or gemcitabine with vinorelbine. For non-squamous types of lung cancer, cisplatin with pemetrexed is an option, though it’s unclear how often this is used specifically for ASC given its mixed histology. If patients are not strong enough for combination therapy, single chemotherapy drugs may be given instead.[7]
Targeted therapy represents an important treatment option when specific genetic mutations are found in the tumor. About 30 percent of adenosquamous carcinomas have EGFR mutations. For patients whose tumors test positive for EGFR mutations, drugs called EGFR tyrosine kinase inhibitors (EGFR-TKIs) such as erlotinib and gefitinib can be effective therapeutic strategies for advanced disease. Other EGFR-targeted drugs like osimertinib, lazertinib combined with amivantamab, or amivantamab alone for certain EGFR mutations may also be options.[1][5][7]
For the approximately 5 percent of ASC patients who have ALK rearrangements, targeted therapy with drugs like crizotinib may be considered, though studies specifically examining crizotinib in ASC are very limited. If testing reveals other targetable mutations, additional targeted therapies might be available.[1][4][5]
Immunotherapy, which helps the body’s immune system fight cancer, may be a potential treatment choice for ASC patients. Immune checkpoint blockade therapy works by removing brakes on the immune system, allowing it to recognize and attack cancer cells more effectively. Studies have found that PD-L1 expression, a marker that can predict immunotherapy response, is present in about 11 percent of the adenocarcinoma component and 28 percent of the squamous component in ASC tumors. This suggests immunotherapy could benefit some patients with this disease.[1][5]
Radiation therapy and other palliative approaches play important roles in managing stage IV disease. Radiation can relieve symptoms by shrinking tumors that cause pain, shortness of breath, or other problems. Procedures to remove airway blockages, drain fluid from around the lungs or heart, or address other complications help maintain comfort and function.[7]
Prognosis and Survival
The prognosis for stage IV adenosquamous cell lung cancer is generally serious, reflecting both the advanced stage and the aggressive nature of this cancer subtype. Studies indicate that ASC has a relatively poor prognosis compared to other types of non-small cell lung cancer. The overall survival tends to be shorter than for pure adenocarcinoma or squamous cell carcinoma at similar stages.[4]
For context, population-based studies have found that five-year survival rates after surgery for early-stage ASC are around 65 percent, compared to 69 percent for squamous cell carcinoma and 77 percent for adenocarcinoma. These differences become more pronounced in advanced stages. However, it’s important to remember that survival statistics are averages based on large groups of people and cannot predict what will happen to any individual patient.[4]
Several factors influence prognosis in stage IV disease. The extent of spread matters: cancer that has metastasized to multiple sites typically has a poorer outlook than cancer limited to one distant location. The presence of targetable genetic mutations can improve prognosis, as these patients may respond well to targeted therapies. Overall health and functional status also play important roles, as patients who are stronger can typically tolerate more intensive treatments.[4]
It’s worth noting that advances in treatment over recent years have improved outcomes for many patients with advanced lung cancer. The development of targeted therapies and immunotherapies has given doctors more tools to help patients live longer with better quality of life. While stage IV disease remains very serious, these advances offer hope for continued progress in managing this challenging cancer.[2]
